NEU 4.57% $21.95 neuren pharmaceuticals limited

Acadia, page-623

  1. 1,592 Posts.
    lightbulb Created with Sketch. 141
    I agree, but even ignoring NNZ-2591, it just frustrates me that the ownership stake in Daybue isn't being valued correctly by the market.

    I know I am preaching to the converted here...

    The market gives us no credit for the fact we are cash flow positive, have reported a net profit after taxes for 2023, and we have huge growth opportunity backed by solid intellectual property and fantastic execution by a fantastic management team who have shown that they can monetise their IP without crushing shareholder value.

    Investors would rather buy GYG at a circa 3b~ for 'underlying' EBIT of 12m in FY24 only growing to 25.4m FY25. The NPAT being negative (-2.2m) due to deprecation of running a business like that. Seems like a bargain hey? For comparison our profit before tax for FY2023 was 205.1m.

    Last edited by htae39: 25/06/24
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$21.95
Change
0.960(4.57%)
Mkt cap ! $2.805B
Open High Low Value Volume
$21.50 $22.13 $21.50 $7.780M 356.2K

Buyers (Bids)

No. Vol. Price($)
19 764 $21.95
 

Sellers (Offers)

Price($) Vol. No.
$21.97 10 2
View Market Depth
Last trade - 14.22pm 17/07/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.